API Impurity Profiling for Canadian Drug Submissions: What Health Canada Reviewers Actually Expect

A 99.5% pure API looks great on a certificate of analysis. The problem is Health Canada wants to know exactly what’s in the other 0.5% — and “unknown impurities” is not an acceptable answer in a New Drug Submission (NDS) or Abbreviated New Drug Submission (ANDS).

Impurity profiling is one of those areas where sponsors consistently underestimate the documentation burden. We see it regularly: a technically sound CMC package, well-executed manufacturing controls, and then a 90-day review cycle extended because the impurity section didn’t meet the expectations set out in ICH Q3A(R2). Getting this right upfront saves months — and in a competitive drug development timeline, months matter.

The Regulatory Framework: ICH Q3A(R2) and Health Canada’s Alignment

Health Canada adopted ICH Q3A(R2) — the guideline on impurities in new drug substances — in 2009, and it remains the primary reference for APIs in Canadian submissions today. It applies to new molecular entities and to existing compounds introduced through novel routes of synthesis.

But Q3A doesn’t stand alone. A complete impurity package in a Canadian drug submission implicates four separate ICH guidelines:

• ICH Q3B(R2): Degradation products in finished drug products
• ICH Q3C(R8): Residual solvents — class designations and permitted daily exposure limits
• ICH Q3D(R2): Elemental impurities — adopted by Health Canada in 2018
• ICH M7(R2): Assessment and control of DNA-reactive (mutagenic) impurities

Reviewers at Health Canada’s Therapeutic Products Directorate (TPD) cross-reference all four. Missing one creates a deficiency notice almost every time. Canada’s GMP guidelines, which inform how manufacturing processes are expected to be designed and controlled, also set the backdrop — if your process isn’t generating a consistent impurity profile batch to batch, that’s both a GMP concern and an impurity characterization problem simultaneously.

Understanding the Three Threshold Tiers

The core of ICH Q3A is a tiered system based on impurity levels expressed as a percentage of the API. Three thresholds govern what you need to do, and they shift depending on the maximum daily dose:

Reporting threshold: 0.05%, or 1.0 mg/day (whichever is lower). Any impurity at or above this level must appear in your specifications and batch analysis data. No exceptions.

Identification threshold: 0.10% for drugs with a maximum daily dose of ≤2 g, or 0.05% for higher doses. Impurities at or above this level must be structurally characterized. “Unidentified peak at RRT 0.85” is not a specification entry — it’s a deficiency waiting to happen.

Qualification threshold: 0.15% for daily doses ≤2 g, or 0.05% for higher doses. Impurities at or above this level require a toxicological justification, whether drawn from published literature, prior human exposure data, structural analogy to known safe compounds, or dedicated safety studies.

Where sponsors most often get tripped up is that qualification zone between 0.10% and 0.15%. An impurity at 0.12% needs to be identified, but not yet formally qualified. One at 0.17% needs both — and if the qualification rationale is absent from the submission, a deficiency notice arrives before the 30-day screening period is even over.

It’s also worth being explicit about something the guideline doesn’t make loud enough: these thresholds apply per individual impurity. A profile carrying five separate impurities each at 0.10% may not trigger qualification individually, but the aggregate impurity burden becomes part of the safety narrative and reviewers will ask about it if it isn’t addressed proactively.

Residual Solvents and Elemental Impurities: Separate Guidelines, Non-Negotiable Requirements

Residual solvents under ICH Q3C are reported entirely separately from organic impurities. Their limits are expressed as permitted daily exposures (PDEs) in mg/day — not as weight percentages — calculated from the toxicological profile of each solvent and your product’s daily dose.

Class 1 solvents (benzene, carbon tetrachloride, 1,2-dichloroethane, and a handful of others) are essentially prohibited in pharmaceutical manufacturing. Class 2 solvents have defined PDEs: dichloromethane, for example, carries a PDE of 6.0 mg/day under oral exposure. Class 3 solvents like ethanol and isopropanol have more permissive limits, though they still need to be tested and reported.

What’s commonly overlooked: if a Class 2 solvent was used three synthetic steps upstream — not in the final crystallization but earlier in the route — trace carryover is still possible. Your validated residual solvent method needs to cover every solvent used across the full synthetic route, not just the last step. Health Canada expects to see that coverage demonstrated in the analytical method development summary.

For elemental impurities, the 2018 adoption of ICH Q3D(R2) was a meaningful shift for the Canadian regulatory landscape. The old heavy metals Limit Test — the colourimetric method from Ph.Eur. 2.4.8 or USP <231> — is no longer considered adequate for new submissions in most contexts. ICH Q3D establishes PDEs for 24 elements across oral, parenteral, and inhalation routes, and requires a formal elemental impurity control strategy document as part of the submission.

ICP-MS has become the method of choice for Q3D analyses. Sub-ppb detection limits are routinely achievable, which is necessary for elements like cadmium (oral PDE: 2 µg/day) and arsenic (oral PDE: 15 µg/day). If your testing partner is still running heavy metals by colourimetric endpoint and describing it as a Q3D-compliant analysis, that discrepancy needs to be resolved before the package goes to Health Canada.

Mutagenic Impurities Under ICH M7(R2): An Entirely Different Standard

If routine impurity profiling has a high bar, mutagenic impurities represent a separate discipline entirely. DNA-reactive compounds — often still called genotoxic impurities in older literature — cannot be “qualified” at 0.15% the way an ordinary degradation product can. The acceptable intake limits under ICH M7(R2) are expressed in micrograms per day, derived from lifetime cancer risk projections at a 1-in-100,000 risk level.

The default Threshold of Toxicological Concern (TTC) for a mutagenic impurity is 1.5 µg/day for a lifetime exposure scenario. That’s not a typo. For context, 1.5 µg/day at a 10 mg/kg oral dose represents roughly 15 ppb in the drug substance. Standard HPLC at 0.05% would never detect it — which is exactly why M7 demands purpose-built analytical methods with much lower LOQs, typically using LC-MS/MS.

Structural alerts that commonly trigger an M7 assessment include:

• Alkylating agents (alkyl halides, epoxides, sultones)
• Aromatic amines, particularly if the amine is on an electron-poor ring
• Hydrazines, hydrazides, and semicarbazides
• Nitro-compounds and N-nitroso compounds
• Certain aldehyde-containing structures

Every synthetic route should undergo a prospective M7 assessment using validated in silico tools — Derek Nexus, Sarah Nexus, or equivalent platforms — as part of CMC development. Health Canada’s guidance aligns with ICH M7’s explicit requirement for both computational and expert-review assessments. A one-line declaration that “no mutagenic alerts were identified” without accompanying software outputs and expert commentary will not survive a review cycle.

For complex multi-step synthetic routes, M7 assessment documents of 40 or more pages are not unusual. Reviewers at TPD are increasingly experienced with these, and they notice when the assessment is shallow.

Building an Impurity Profile That Holds Up Under Canadian GMP Review Standards

The following approach reflects what a defensible impurity section in a Canadian NDS or ANDS looks like in practice.

Map the full synthetic route before you develop a single analytical method. Every reagent, intermediate, byproduct, and solvent needs to be inventoried. Potential impurities arise from unreacted starting materials, over-reacted intermediates, stereoisomers, hydrolysis products, oxidative degradants, and carryover from prior steps. The analytical strategy flows from this map — not the other way around.

Develop targeted methods for each impurity class. A single reversed-phase HPLC method covers most organic impurities, but you’ll also need headspace GC for residual solvents and ICP-MS for elemental impurities. Method validation per ICH Q2(R1) is required for all of them — specificity, linearity, LOQ, intermediate precision, and solution stability at minimum.

Run forced degradation studies to establish stability-indicating capability. Acid hydrolysis, base hydrolysis, oxidative conditions, thermal stress, and photolytic stress generate the degradation profile that informs your specification limits and demonstrates that your HPLC method is truly stability-indicating. Health Canada specifically looks for this data in the analytical section.

Write the qualification rationale before submission — ideally before Phase III. Sponsors who try to prepare toxicological justifications for impurities above the qualification threshold in the weeks before NDS filing are setting themselves up for a difficult review. These justifications take time, particularly if literature data doesn’t exist and structural analogy arguments need to be built carefully.

Use published monographs and databases as qualification anchors where possible. USP, Ph.Eur., and BP monographs sometimes include limits for known process impurities with embedded safety rationale. ICH’s own worked examples and the European Medicines Agency’s impurity guideline annexes are also legitimate sources. These pathways are underused and can eliminate the need for new toxicology studies in the right circumstances.

Canada’s GMP framework — specifically the Health Canada GMP guidelines under Part C, Division 2 of the Food and Drug Regulations — requires that manufacturing processes be designed to produce consistent quality. A batch-to-batch variable impurity profile isn’t just a chemistry problem; it raises GMP questions about process understanding and control. Aligning your impurity characterization work with your process development narrative is the kind of integration that distinguishes submissions that move quickly from those that don’t.

One thing worth saying clearly: Health Canada’s CMC review teams have raised their expectations significantly over the past five to six years. Packages that drew only minor queries in 2019 are now receiving full deficiency notices on impurity sections. Sponsors preparing submissions to older standards — or those using regulatory writing teams unfamiliar with current Canadian expectations — are finding out the hard way through extended review cycles and costly manufacturing holds.

Getting impurity profiling right isn’t only about clearing a regulatory hurdle. It’s about knowing what you’re actually putting into a patient and being able to demonstrate that it’s safe. Health Canada’s standards exist for that reason, and meeting them properly is worth the investment.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• USP Method Validation and API Testing for US FDA Submissions — ISO 17025-accredited laboratory testing and ICH Q2(R1) method validation services for US regulatory submissions.
• Pharmaceutical Impurity Testing for EU EMA Submissions — European regulatory compliance, REACH, and API characterization services for manufacturers entering EU markets.